AGATA, a pilot study to implement personalized therapy for patients with advanced or metastatic breast cancer

The AGATA study is the first genomic screening platform for advanced breast cancer ever attempted in Spain. By this molecular platform SOLTI aimed to increase the likelihood of a patient being included in a targeted clinical trial based on the tumor molecular profiling. Genomcore provided a secure and compliant federated platform to store and analyze the clinical and genomic data within the project.